{"id":"binifibrate","rwe":[],"tags":[{"label":"binifibrate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"biniwas","offLabel":[],"synonyms":["binifibrate","biniwas"],"timeline":[],"brandName":"Biniwas","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"binifibrate","explanation":"Think of it like a sponge that soaks up excess cholesterol in the gut and helps remove it from the body. This process helps to lower the amount of cholesterol in the blood, which can reduce the risk of heart disease. By reducing the amount of cholesterol in the blood, Biniwas may help to slow the progression of atherosclerosis, a condition in which plaque builds up in the arteries.","oneSentence":"Biniwas works by inhibiting the reabsorption of bile acids in the gut, which helps to lower cholesterol levels in the blood.","technicalDetail":"Biniwas is a fibric acid derivative that acts as an inhibitor of the sodium-dependent bile acid transporter (NTCP), which is responsible for the reabsorption of bile acids in the liver. By inhibiting NTCP, Biniwas increases the excretion of bile acids into the bile, which in turn increases the excretion of cholesterol into the bile. This leads to a decrease in the amount of cholesterol available for absorption in the gut, resulting in a decrease in circulating cholesterol levels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/372","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BINIFIBRATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:59:52.554794","biosimilars":[],"competitors":[],"genericName":"binifibrate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"2275","NDDF":"001052","UNII":"9NGZ4GPE20","CHEBI":"CHEBI:135800","VANDF":"4017661","INN_ID":"4956","RXNORM":"7393","UMLSCUI":"C0053612","ChEMBL_ID":"CHEMBL2106582","KEGG_DRUG":"D07529","DRUGBANK_ID":"DB00627","PDB_CHEM_ID":" NIO","PUBCHEM_CID":"68884","SNOMEDCT_US":"273943001","MESH_DESCRIPTOR_UI":"D002995","MESH_SUPPLEMENTAL_RECORD_UI":"C038877"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biniwas, also known as Binifibrate, is a small molecule drug in the binifibrate class. It is a lipid-lowering agent, but its exact target and mechanism of action are unknown. The commercial status of Biniwas is unclear, and it is not approved by the FDA. Further information on its pharmacokinetics, safety, and efficacy is also lacking. As a result, Biniwas is not widely recognized or used in clinical practice.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}